Our People

The EBAMed team is diversified in background, knowledge, and culture to provide the broadest possible perspective. They bring together experience from different types of companies, ranging from start-ups to well established multinationals.

Our experts are creative with a track record of success in the development and global commercialization of cardiac software, medical devices and drug. They are passionate people, driven by innovation, with a clear focus on patient benefit and proving this benefit with clinical-based evidence.

The R&D team is conducted in-house, allowing it to retain greater control over its proprietary technology.

Board Members

Giovanni Leo

Co-Founder

Giovanni Leo is partner of Innogest Capital since 2018. Prior to Innogest Giovanni was VP of R&D at St Jude Medical since the acquisition of Endosense in 2013, which he co-founded to develop a novel technology for the catheter ablation treatment of cardiac arrhythmias. Formerly he was the director of the Geneva offices for Acrostak Corp., a Boston-Scientific funded medical device company that developed the only European system for vascular brachytherapy. Giovanni earned an Executive MBA in Management and Corporate Finance from the HEC of Lausanne, following a degree in management engineering from Politecnico of Milano, Italy.

Rupa Basu

Chairman

Rupa Basu is a mission-driven MedTech executive with a proven track record of building and scaling transformative healthcare technologies from inception to exit. She brings deep expertise in fundraising, go-to-market strategy, and organizational scaling, having raised private capital and consistently delivered strong revenue growth and shareholder value. Most recently, Rupa served as Chief Commercial Officer and President of OrganOx, a University of Oxford spinout focused on advancing organ transplantation technology. There, she led global commercial, clinical, and operational strategy, scaling revenue 45x in under three years, achieving positive cash flow, and playing a lead role in the company’s successful acquisition by Terumo Group for $1.5bn. She also serves as a senior advisor for Sofina, an investment company listed on EuroNext. Earlier in her career, Rupa held senior leadership roles at Biotronik, St Jude Medical/Abbott and Bayer Pharmaceuticals.
.

Marlou Janssen

Independent Director

Marlou Janssen-Counotte is a senior MedTech Executive with 25+ years of experience as Vice President, President, General Manager, driving business development and comprehensive marketing & clinical operations through effective strategy execution, solutions planning and delivery, and transformational leadership. Accomplished General Manager adept at overseeing all-round business management in introducing growth-oriented strategies, successfully executing sales and marketing plans, and directly managing high-performing cross-functional teams within large- and medium-sized organizations such as Medtronic, St. Jude Medical, Biotronik, Philips. As for other ongoing assignments Marlou currently holds a non-executive board position at Acarix AB/SA, Field Medical Inc., and Inspiration Healthcare Group.“

Barbara Castellano

Director

Barbara is Partner in Panakes SGR. Previously he was founder and CEO of Techwald SPA, a financial holding. She has a strong knowledge of cardiovascular sector acquired as former Director of Clinical Affairs, Certifications, Registrations and Quality Assurance at CID SpA (now Alvimedica) and as former Director of Business Development & Global Marketing Director for the Heart Valves Business Unit at Sorin (now Livanova). Barbara holds a Msc in Medicinal Chemistry and Technology from University of Perugia and an executive MBA from SDA Bocconi.

Clinical Advisors

Douglas Packer

Co-Founder & Key Advisor

Douglas L. Packer, MD, is a Professor of Medicine, and the John M. Nasseff, Sr., Professor in Cardiovascular Diseases in the Department of Cardiovascular Diseases, Division of Cardiac Electrophysiology, at Mayo Clinic Rochester. He is Director of the Translational Electrophysiology Research Laboratory. Dr. Packer is internationally known in cardiac electrophysiology.

He received the MD degree at the University of Utah and completed an internship, residency and fellowship at Duke University, where he was on staff before coming to Mayo. His honors and awards include the ACC 2019 Distinguished Scientist Award (Translational) (2019), the Distinguished Service Award from Brigham Young University, the Haskel Schiff Award in Internal Medicine from Duke University, the Eric Prystowsky Advocate for Patients Award, and a variety of Visiting Professorship awards.

Dr. Packer is active in the Heart Rhythm Society where he is a past president and member of the Board of Trustees. He is also active in the American Heart Association and the American College of Cardiology. He has served/currently serves on editorial boards for the Circulation Arrhythmia & Electrophysiology, American Heart Journal, the Journal of Cardiovascular Electrophysiology, Heart Rhythm journal, and the (EP) Journal of the American College of Cardiology. He also has served on multiple National Heart, Lung, and Blood Institute work groups on atrial fibrillation, ablation and planning for future NIH studies.

Dr. Packer has been an active teacher and mentor, and also lectures widely on cardiac arrhythmias. He has written or co-authored more than 379 publications. He has lectured extensively in national and international meetings, giving over 1,872 invited lectures in 41 countries. He has served on the executive committee of a number of NIH multicenter randomized clinical trials, Including the MUSTT, SCD-HeFT, and HAT Trials. Dr. Packer is also the International Principal Investigator of the recently reported NIH CABANA Trial. In this capacity he led the consortium of centers directing the trial. He is the PI of the Thermedical VT Needle Electrode study, and on the Executive Committee of the LESS VT Study.

Dr. Packer is a Mayo Clinician Investigator. His translational work focuses on the mechanisms and ablation of atrial fibrillation and other cardiac arrhythmias, autologous fibroblast modulation of electrical impulse propagation in the heart, and the development of carbon particle catheter-free ablation of arrhythmias. His clinical work investigates 4/5 dimensional integrated image-guided ablation, and the development of new energy sources for the modification of cardiac tissue. His work has been funded in part by private foundations, the American Heart Association, and the NIH. A key part of his research is the development of the US Catheter Free Particle Therapy Ablation Program. He is also the PI of the Extracorporeal Particle Therapy Ablation Using Proton and Carbon Beams, that is currently under way. Dr. Packer holds US and European patents in the development of intracardiac ultrasound and 4/5D imaging, and particle therapy ablation.

Ugo Amaldi

Co-Founder & Key Advisor

Ugo Amaldi was Director of research at the National Health Institutes in Rome (ISS), where he worked on radiation physics and nuclear physics. Since 1973 he has been Senior Scientist at CERN. He is well known for his achievements as a particle physicist, in particular for the creation and direction of the DELPHI Collaboration. He has been president of the Italian Foundation TERA (Tumour therapy with hadronic radiations) from its creation in 1992 till 2018, when he created the Italian National Centre for Hadron Therapy CNAO in Pavia, and is now President emeritus. He has been full Professor of Physics at Milano University and, at present, is Distinguished Affiliated Professor at the Technische Universität München (TUM). Two million Italian high-school pupils have studied physics on his about forty textbooks and 600 publications account his scientific activities in the fields of physics of atoms, nuclei, fundamental particles, accelerators and in medical physics.

Management Team

Marcin Gołębicki

Chief Executive Officer

Marcin Gołębicki is a C-level executive, senior leader, and entrepreneur with nearly 30 years of experience in the life sciences and med-tech sectors. He has led large-scale international organizations, including direct oversight of a P&L exceeding $650 million USD and a team of over 600 professionals and agents.

Throughout his career, Marcin has held senior leadership roles at globally recognized companies including Johnson & Johnson, Boston Scientific, Abbott St. Jude Medical, EPD Solution (Philips Company), Medicalgorythmics, EP Solutions SA and RnavieSensing. His leadership philosophy is rooted in integrity, purpose-driven performance, and fostering inclusive, high-achieving teams within multicultural and international environments. Alongside his corporate track record, Marcin has built a successful career as a serial entrepreneur, founding and scaling ventures in the life sciences space. He is equally recognized as a highly skilled turnaround executive, with a proven ability to reposition challenged organizations, restore operational performance, and drive sustainable growth.

In addition to his executive career, Marcin serves as an advisor, consultant, and Supervisory Board Member to leading business organizations. He holds academic credentials from Indiana University, the University of Minnesota, and Harvard University (postgraduate). Since 2010, he has been a YPO Member in Europe, actively supporting the development of next-generation managers and leaders.

Adriano Garonna

Chief Technology Officer

Adriano Garonna is a physicist with over 10 years of experience in the technologies used for medical treatments with accelerated particle beams, matured in academia (EPFL), both public and private research institutes (CERN, TERA Foundation), as well as clinical centers (Paul Scherrer Institute in Switzerland, EBG MedAustron Gmbh in Austria).

Olivier Coquoz

Head of R&D

Olivier Coquoz has a diploma of Physics Engineer and a PhD in Sciences of the EPFL in Biomedical Optics, a Postdoc at Beckman Laser Institute in UC Irvine. He worked for 3 startups and has 15-year Experience in developing new products (medical devices, laboratory equipment). He also has large industrial experience. He joins EBAMed from the Wyss Center, where he was Chief Operating Officer.